Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study

University of Milano Bicocca700 enrolled

Overview

The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion

This single-center prospective study will enroll approximately 700 hematologic patients who access to Haematological Division (San Gerardo Hospital, Monza, Italy) in order to perform their routine blood tests to monitor their hematological conditions. Evaluation of Sars-Cov-2 IgG specific antibodies will be performed on left-over biological material (serum or plasma) collected during routine blood tests run between 30 and 60 days after the administration of the second vaccine dose. Furthermore, in each patient who has failed seroconversion (absence of specific antibodies for circulation), his cellular immune response will be assessed using an additional blood sample collected during routine blood tests. These samples will be collected within 9 months of the completion of the vaccination series and will be used to evaluate the plasma INF-γ release using QuantiFERON SARS-CoV-2 test.

Study Type

OBSERVATIONAL

Enrollment

700

Conditions

Hematologic Diseases

Interventions

IgG antibodies to Sars-Cov-2BIOLOGICAL

Samples will be collected between 30 and 60 days after second vaccine dose.

QuantiFERON SARS-CoV-2 testBIOLOGICAL

Samples will be collected within 9 months after completion of the vaccination series

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed and dated EC-approved informed consent * Hematological disease defined according to World Health Organization (WHO) criteria * Female or male, 18 years of age or older * ECOG performance status 0-3 * Willingness and ability to comply with routine clinical practice and study procedures * Regular vaccination against SARS-CoV-2 according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021). * Routine blood test planned between 30 and 60 days after administration of the second vaccine dose according to regular hematological follow up. * Routine blood test planned no later than 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies). Exclusion Criteria: * Preventive vaccination against SARS-CoV-2 not administered according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021) * Evidence of previous infection with the SARS-Cov-2 virus. * Routine blood test not planned between 30 and 60 days after administration of the second vaccine dose. * Routine blood test not planned within 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies).

Locations (1)

San Gerardo Hospital

Monza, Lombardy, Italy

Outcomes

Primary Outcomes

Rate of seroconversion in hematological patients who received a mRNA SARS-CoV-2 vaccine

Seroconversion is defined as a post-vaccination SARS-CoV-2 IgG antibody titer \>33.8 Binding Anticorpal Unit (BAU)/ml.

Time frame: Between 30 and 60 days after the administration of the second vaccine dose

Secondary Outcomes

To compare the seroconversion rate in haematological patients versus healthy subjects.

Time adjusted rate of seroconversion after vaccination in hematological patient and healthy population.

Time frame: Between 30 and 60 days after the administration of the second vaccine dose

To correlate the rate of seroconversion in hematological patients to the specific haematological diseases.

Rate of seroconversion per type of haematological condition

Time frame: Between 30 and 60 days after the administration of the second vaccine dose

To correlate the rate of seroconversion to previous therapies

Rate of seroconversion per specific treatment.

Time frame: Between 30 and 60 days after the administration of the second vaccine dose

To assess the efficacy of vaccine by estimating how many patients will be infected by SARS-CoV-2 in the 9 months after the administration of the second vaccine dose.

Rate of patients with a positive RT-PCR-SARS-CoV-2 test in the 9 months after the administration of the second vaccine dose

Time frame: Within 9 months after the administration of the second vaccine dose

To analize T-cell response in those patients who will result negative for specific antibodies anti-Sars-Cov-2 after two doses of mRNA SARS-Cov-2 vaccination

Rate of patients with a positive QuantiFERON-SARS-CoV-2 test after the demonstration of seroconversion failure until the end of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.